ArticleCancer biology & therapy2018

CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.

Nicholas C Nicolaides et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.